Breaking News

Genomic analysis uncovered genetic, transcriptional, and drug response shifts between different cultures, or "strains," of the same human cancer cell lines.

LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

The FDA granted the assay's status based on its ability to detect both ovarian and pancreatic cancer in asymptomatic individuals over the age of 65.

The revenue growth was driven by strong sales of products including the company's Epi proColon blood-based colorectal cancer screening test.

The agency's regulatory plan differs in key areas from a draft of the Diagnostic Accuracy and Innovation Act that had shored up lab industry support.

FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.

The revenue growth was primarily driven by HTG's collaborative development services activities with pharmaceutical partners including Qiagen.

The decline was in line with what the company preliminarily reported last month, reflecting much lower collaboration revenues than in the prior year period.

The company said Q2 sales increased 11 percent on a currency-neutral basis, driven by growth in both its Life Science and Clinical Diagnostics segments.

Sales were driven by the cardiac testing products acquired last year from Alere and offset a decline in rapid immunoassay sales tied to the flu season.

Based on the strength of its quarterly financial performance, Invitae said it is now expecting annual revenues of between $135 million and $140 million for 2018.

The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.

The financing will support growth in Maravai's three life science segments: bioprocess impurity testing, oligonucleotide synthesis, and protein detection.

Nonprofit eMQT will use Shivom's decentralized blockchain platform to store and share genomic data of sickle-cell diseases in underserved regions.

Protein platforms revenues grew 21 percent, while biotechnology revenues were up 18 percent, and diagnostic revenues increased 2 percent.

With panel sequence data from Ambry's clinical lab and a TNBC research consortium, researchers saw risky hereditary variants in BRCA1/2 and other genes.

Proceeds from the offering could be used to fund acquisitions, to repay existing debts, or for working capital.

As part of the agreements, the distributors have committed to purchase a minimum number of Curetis' molecular diagnostic systems over three years.

The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.

During the quarter, the number of billable tests delivered rose to 5,700, and the CEO said that recent investments in the firm were showing a positive impact.

The lawsuit makes broad accusations that companies stole trade secrets related to universal array technology.

Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.

Indian DTC genomics company Mapmygenome has enlisted Israel-based Digital DNAtix to move its interpretation and personalized medicine services to a blockchain.

The Suzhou, China-based company is developing medicines and molecular diagnostics based on its gene editing and delivery technologies.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.